Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | WDR5 | P61964 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.58 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | LDHA | P00338 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.56 |
| ▸ | ATIC | P31939 | 1/20 | 0.56 |
| ▸ | ME2 | P23368 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11067214 | 0.91 | POLB (0.61) | POLBGPR35CYP2D6WDR5MEN1 | |
| SCHEMBL8057702 | 0.90 | MEN1 (0.70) | POLBGPR35CYP2D6WDR5MEN1 | |
| SCHEMBL8463472 | 0.90 | POLB (0.56) | POLBGPR35CYP2D6WDR5MEN1 | |
| SCHEMBL24891573 | 0.90 | POLB (0.59) | POLBGPR35CYP2D6WDR5MEN1 | |
| SCHEMBL6349823 | 0.87 | POLB (0.54) | POLBGPR35CYP2D6WDR5MEN1 | |
| SCHEMBL28464804 | 0.87 | MEN1 (0.75) | POLBGPR35CYP2D6WDR5MEN1 | |
| SCHEMBL3391301 | 0.86 | POLB (0.69) | POLBGPR35CYP2D6WDR5MEN1 | |
| SCHEMBL9254751 | 0.85 | HNF4A (0.58) | POLBGPR35CYP2D6WDR5MEN1 | |
| SCHEMBL9938080 | 0.85 | GPR35 (0.62) | POLBGPR35CYP2D6WDR5MEN1 | |
| SCHEMBL5380957 | 0.83 | ME2 (0.70) | POLBGPR35CYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114409885-B | Low-extraction motor film and preparation method thereof | 宁波勤邦新材料科技有限公司 | 2023-06-02 | — | — | CN | claimed |
| CN-114409885-A | Low-extraction motor film and preparation method thereof | 宁波勤邦新材料科技有限公司 | 2022-04-29 | — | — | CN | claimed |
| CN-111686798-A | BINOL axis chiral thiourea organic catalyst for preparing spiro tetrahydrothiophene | 秦婷 | 2020-09-22 | — | — | CN | claimed |
| US-9622995-B2 | Treatment of disorders associated with G protein-coupled receptor 35 (GPR35) | Temple University—Of the Commonwealth System of Higher Education (US) | 2017-04-18 | — | — | US | claimed |
| US-20150265561-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | NATIONAL INSTITUTES OF HEALTH | 2015-09-24 | — | — | US | claimed |
| US-9040583-B2 | Treatment of disorders associated with G protein-coupled receptor 35 (GPR35) | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2015-05-26 | — | — | US | claimed |
| US-20120122987-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-05-17 | — | — | US | claimed |
| WO-2011011235-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-01-27 | — | — | WO | claimed |
| EP-1430950-B1 | Hydroformylation of unsaturated compounds using polymeric phosphite ligands | INVISTA TECH SARL (US) | 2006-02-22 | — | — | EP | claimed |
| EP-1225978-B1 | HYDROFORMYLATION OF UNSATURATED COMPOUNDS USING POLYMERIC PHOSPHITE LIGANDS | INVISTA TECH SARL (US) | 2005-03-16 | — | — | EP | claimed |
| JP-2003533337-A | — | — | 2003-11-11 | — | — | JP | claimed |
| US-20020177737-A1 | Hydroformylation of unsaturated compounds using polymeric phosphite ligands | INVISTA NORTH AMERICA S.A.R.L. | 2002-11-28 | — | — | US | claimed |
| EP-1225978-A1 | HYDROFORMYLATION OF UNSATURATED COMPOUNDS USING POLYMERIC PHOSPHITE LIGANDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-07-31 | — | — | EP | claimed |
| US-6420611-B1 | GROUP 8 METAL WITH PHOSPHITE POLYMERS FROM POLYHYDRIC ALCOHOL, AMINE AND PHOSPHOCHLOROIDITE | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-07-16 | — | — | US | claimed |
| EP-1216268-A1 | POLYMERIC PHOSPHITE COMPOSITION AND HYDROCYANATION OF UNSATURATED ORGANIC COMPOUNDS AND THE ISOMERIZATION OF UNSATURATED NITRILES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-06-26 | — | — | EP | claimed |
| US-20010049431-A1 | Polymeric phosphite composition and hydrocyanation of unsaturated organic compounds and the isomerization of unsaturated nitriles | INVISTA NORTH AMERICA S.A.R.L. | 2001-12-06 | — | — | US | claimed |
| US-6284865-B1 | POLYESTER OR POLYAMIDE CONTAINING PHOSPHITE GROUPS PREPARED FROM AN AROMATIC DIHYDROXYPOLYCARBOXYLIC ACID, A POLYOL OR DIAMINE AND A PHOSPHOROCHLORIDITE | E. I. DU PONT DE NEMOURS AND COMPANY | 2001-09-04 | — | — | US | claimed |
| WO-2001021308-A1 | HYDROFORMYLATION OF UNSATURATED COMPOUNDS USING POLYMERIC PHOSPHITE LIGANDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-03-29 | — | — | WO | claimed |
| WO-2001021684-A1 | POLYMERIC PHOSPHITE COMPOSITION AND HYDROCYANATION OF UNSATURATED ORGANIC COMPOUNDS AND THE ISOMERIZATION OF UNSATURATED NITRILES | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-03-29 | — | — | WO | claimed |
| US-4224221-A | Modifier composition for azo pigments based on 2-hydroxy-3-naphthoic acid | AMERICAN CYANAMID COMPANY (US) | 1980-09-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177737-A1 | Hydroformylation of unsaturated compounds using polymeric phosphite ligands | PHOSPHO1, PPIP5K2, PF4 | POLB 1285/4885GPR35 3342/4885CYP2D6 3542/4885 |
| US-20120122987-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | GPR35, GPR68, GRM5 | POLB 4617/4885GPR35 1/4885CYP2D6 4196/4885 |
| US-20150265561-A1 | TREATMENT OF DISORDERS ASSOCIATED WITH G PROTEIN-COUPLED RECEPTOR 35 (GPR35) | GPR35, GPR68, GRM5 | POLB 4617/4885GPR35 1/4885CYP2D6 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.